← 프로그램 목록
Phase 1Active
비교

DS-8201a (DP2)(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumors 표적 치료제로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 74.1% (ClinicalTrials.gov NCT03523585). PK: t½ 100 days. 차별점: first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is s.

출처: ClinicalTrials.gov · PubMed · openFDA최근 동기화됨

개요

임상 2026년 7월 8일 (6일 전)PK/독성 2026년 7월 8일 (6일 전)

Advanced Solid Tumors

Advanced Solid Tumors

Active

Technology

구조모아 · Exatecan/DXd (TOP1)

CAR T cells

release

linker enables a stable, high-DAR exatecan-based HER2 ADC with potent antitumor activi

retroviral therapy (ART), resulting in rebound viremia after treatment interruption

first-in-class antineoplastic agent for acute myeloid leukemia (AML), exhibits a distinctive pyrrolo[2,3-b]pyridine scaffold, and is s

Mechanism of Action

t cells promote reactivation

topoisomerase I inhibitor, has been challenged by its hydrophobicity, leading to aggregation, rapid clearance, and off-target toxicit

biomarker can inform prognostic decisions in patients at high risk for death from withdrawal of life-sustaini

downregulation of PPARγ and C/EBPα

임상시험 & 결과

차트 로드 중…

임상 한눈에 보기

  • 76건의 ClinicalTrials.gov 임상 기록
  • Phase·Status 요약은 enrollment 상위 표본 기준입니다
  • 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
  • Phase: Phase 3 · Phase 1, Phase 2
  • Status: Active, not recruiting · Recruiting · Completed
  • 주요 endpoint: Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Disease-free Survival (DFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Overall Survival (OS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Distant Recurrence-free Interval (DRFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment · Brain Metastases-free Interval (BMFI) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment
  • 등록된 결과: ORR 74.1%
  • 핵심: This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated…

임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.

참고문헌

자주 묻는 질문

DS-8201a (DP2)은 어떤 치료제인가요?
DS-8201a (DP2)(Daiichi Sankyo / AstraZeneca)은 Advanced Solid Tumors 표적 항체로, Advanced Solid Tumors 영역에서 개발·상용화 중입니다. 데이터는 바이오모아 (BioMoa)에서 ClinicalTrials.gov·openFDA·PubMed 기반으로 정리합니다.
DS-8201a (DP2)의 임상 단계는?
DS-8201a (DP2)의 현재 단계는 Phase 1입니다.
비슷한 프로그램과 어떻게 비교하나요?
바이오모아 (BioMoa) 비교 페이지에서 PK/PD, 독성, 임상 효능 지표를 나란히 볼 수 있습니다. 동일 타깃·모달리티 프리셋을 함께 참고하세요.